Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  The Permanente Journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.7812/TPP/18-034PMID 30227909PMCID PMC6141654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.

  2018cited by this paper
• Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis

  2018cited by this paper
• 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018

  2017cited by this paper
• EMPA-REG OUTCOME: The Nephrologist's Point of View.

  2017cited by this paper
• Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

  2017cited by this paper
• Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes

  2017cited by this paper
• Metabolic and hemodynamic effects of sodium‐dependent glucose cotransporter 2 inhibitors on cardio‐renal protection in the treatment of patients with type 2 diabetes mellitus

  2017cited by this paper
• Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

  2017cited by this paper
• Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

  2017cited by this paper
• Are SGLT2 Inhibitors Ready for Prime Time for CKD?

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus

  2017cited by this paper
• Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  2015cited by this paper
• Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

  2014cited by this paper
• Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review

  2014cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper

• The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases

  2025cites this paper
• Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease

  2023cites this paper
• How to use type 2 diabetes meds to lower CV disease risk.

  2019cites this paper